Sam Raha

Sam Raha currently serves as a senior leader at Myriad Genetics, a company specializing in molecular diagnostics and precision medicine with a focus on genetic testing for hereditary cancer and other diseases. His LinkedIn profile indicates extensive expertise in areas relevant to healthcare technology, including strategic growth initiatives within the diagnostics industry.

At Myriad Genetics, Sam holds responsibilities that likely encompass business development, strategic partnerships, and expanding commercial opportunities, leveraging his background in healthcare innovation and market dynamics. Myriad Genetics, as a publicly traded entity with a significant footprint in personalized medicine, positions him at the intersection of advanced biotechnology and healthcare delivery systems, making his role critical in navigating complex regulatory and reimbursement environments.

His profile suggests strong experience in aligning cutting-edge genetic testing solutions with clinical adoption and payer reimbursement, underscoring his understanding of the healthcare ecosystem’s commercial and operational challenges. Sam’s professional trajectory reflects a combination of technical knowledge and business acumen, allowing him to effectively drive revenue growth while ensuring compliance with evolving healthcare standards.

For engagement, Sam’s focus areas likely include collaborations that enhance patient access to molecular diagnostics, optimize healthcare provider workflows, and support data-driven decision making in precision medicine treatments. His profile does not indicate direct involvement in early-stage technology development, but rather strategic scaling and commercialization of proven diagnostic platforms.

By emphasizing partnerships that improve speed-to-market and clinical integration, Sam stands as a key decision-maker who can influence procurement and implementation strategies within Myriad Genetics, making him a pivotal figure for companies offering complementary technologies or services aligned with personalized healthcare and diagnostic innovation.